domingo, 20 de setembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)

View original at globenewswire.com
GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC) BOCA RATON, FL AND TORONTO, ONTARIO, March 16, 2026 (GLOBE NEWSWIRE) -- GNQ Insilico Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GNQ's integration of Genomics, Artificial Intelligence, and Quantum Computing represents a differentiated approach to addressing significant challenges facing drug discovery and development

    60% confidence
  • Partnering with IB Acquisition Corp. marks a pivotal moment for GNQ as we scale our three comprehensive AI-powered platforms to transform pharmaceutical R&D and healthcare delivery

    60% confidence
  • The Transaction is expected to close in the third quarter of 2026

    60% confidence
  • GNQ is well-positioned to capture meaningful market share

    60% confidence
  • The transaction provides resources and public market visibility to expand commercial partnerships and scale solutions to serve pharmaceutical companies, investors and healthcare providers worldwide

    60% confidence
  • GNQ's Drug Simulation Platform and Digital Twins Platform are slated for release later in 2026

    60% confidence
  • The Transaction is expected to provide approximately $15 million in proceeds to GNQ, including a PIPE of up to $10 million and cash held in IBAC trust account

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
Sinalizamos conflitos abertamente ›
Verificado recentemente
Verificado com a fonte original
4,982
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,982 factos verificados com a fonte5,299 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC) — Source | Via News | pt.VIA.NEWS